Congenital Absence of Nitric Oxide Synthase 3 Potentiates Cardiac Dysfunction and Reduces Survival in Doxorubicin- and Trastuzumab-Mediated Cardiomyopathy
- 1 March 2014
- journal article
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 30 (3) , 359-367
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in miceBMC Cardiovascular Disorders, 2011
- Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitorsBreast Cancer Research and Treatment, 2011
- The Cardioprotective Role of Probucol Against Anthracycline and Trastuzumab-Mediated CardiotoxicityJournal of the American Society of Echocardiography, 2011
- Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical TrialClinical Cancer Research, 2009
- Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent PathwaysJournal of Biological Chemistry, 2009
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Deletion of the eNOS gene has a greater impact on the pulmonary circulation of male than female miceAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2005
- Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout MiceCirculation, 2004
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987